Patents by Inventor Rodolfo Fleury Perini

Rodolfo Fleury Perini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING PATIENTS WITH CANCER
    Publication number: 20240010729
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1), a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof and the use of the combination therapies for the treatment cancer.
    Type: Application
    Filed: September 14, 2021
    Publication date: January 11, 2024
    Inventors: Jane Anne Healy, Sujata Shrawankuma Jha, Patricia Marinello, Rodolfo Fleury Perini, Jaqueline Willemann Rogerio
  • METHODS FOR TREATING CANCER OR VON-HIPPEL LINDAU DISEASE USING A COMBINATION OF A PD-1 ANTAGONIST, A HIF-2 ALPHA INHIBITOR, AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20230250182
    Abstract: Provided herein are methods of treating cancer (e.g., RCC) or von-Hippel Lindau disease, which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) a HIF-2? inhibitor; and (c) lenvatinib, or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer.
    Type: Application
    Filed: June 21, 2021
    Publication date: August 10, 2023
    Applicants: Merck Sharp & Dohme LLC, Eisai R&D Management Co., Ltd.
    Inventors: Rodolfo Fleury Perini, Elaine M. Pinheiro, Jacqueline Willemann-Rogerio
  • METHODS FOR TREATING CANCER OR VON-HIPPEL LINDAU DISEASE USING A COMBINATION OF A HIF-2 ALPHA INHIBITOR AND LENVATINIB
    Publication number: 20230210838
    Abstract: Provided herein are methods of treating cancer (e.g., RCC) or von-Hippel Lindau disease, which comprise administering to a human patient in need thereof: (a) a HIF-2? inhibitor; and (b) lenvatinib, or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer or von-Hippel Lindau disease.
    Type: Application
    Filed: June 21, 2021
    Publication date: July 6, 2023
    Applicants: Merck Sharp & Dohme LLC, Eisai R&D Management Co., Ltd.
    Inventors: Rodolfo Fleury Perini, Elaine M. Pinheiro, Jacqueline Willemann-Rogerio
  • METHODS FOR TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, A CTLA4 ANTAGONIST, AND LENVATINIB OR A PHARMACEUTICALLY ACCPETABLE SALT THEREOF
    Publication number: 20230118596
    Abstract: Provided herein are methods of treating cancer (e.g., melanoma or RCC), which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) a CTLA4 antagonist; and (c) lenvatinib represented by Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer.
    Type: Application
    Filed: March 4, 2021
    Publication date: April 20, 2023
    Applicants: Merck Sharp & Dohme LLC, EISAI R&D Management Co., Ltd.
    Inventors: Blanca Homet Moreno, Nageatte Ibrahim, Rodolfo Fleury Perini, Scott J. Diede, Scot W. Ebbinghaus, Rachel Allison Altura
  • COMBINATION CANCER TREATMENT USING A PD-1 ANTAGONIST, AN ILT4 ANTAGONIST, AND LENVATINIB OR SALTS THEREOF
    Publication number: 20230058779
    Abstract: Provided herein are methods of treating cancer (e.g., RCC), which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) an ILT4 antagonist; and (c) lenvatinib represented by Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 23, 2023
    Applicants: Merck Sharp & Dohme LLC, EISAI R&D Management Co., Ltd.
    Inventors: Rachel A. Altura, Philip E. Brandish, Rodolfo Fleury Perini
  • COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER
    Publication number: 20220324979
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
    Type: Application
    Filed: April 20, 2022
    Publication date: October 13, 2022
    Applicants: PFIZER INC., MERCK SHARP & DOHME CORP.
    Inventors: Jean-Francois Andre MARTINI, Jamal Christo Tarazi, Rodolfo Fleury Perini, David J. Mauro
  • COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER
    Publication number: 20200325228
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L 1.
    Type: Application
    Filed: January 14, 2020
    Publication date: October 15, 2020
    Applicants: PFIZER INC., MERCK SHARPE & DOHME CORP.
    Inventors: Jean-Francois Andre Martini, Jamal Christo Tarazi, Rodolfo Fleury Perini, David J. Mauro
  • Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
    Patent number: 10570202
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: February 25, 2020
    Assignees: Pfizer Inc., Merck Sharpe & Dohme Corp.
    Inventors: Jean-Francois Andre Martini, Jamal Christo Tarazi, Rodolfo Fleury Perini, David J. Mauro
  • COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER
    Publication number: 20170166641
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
    Type: Application
    Filed: February 3, 2015
    Publication date: June 15, 2017
    Inventors: Jean-Francois Andre Martini, Jamal Christo Tarazi, Rodolfo Fleury Perini, David J. Mauro